Abstract FR477: Implementing the CDC’s Hypertension Management Program Toolkit in a Federally Qualified Health Center (FQHC)

Introduction: The CDC’s HTN Management Program (HMP) Toolkit provides strategies to improve HTN control rates. The study implemented components of the HMP Toolkit in a FQHC to examine the impact on HTN control. Hypothesis: Does implementing components of the HMP Toolkit over 12 weeks improve BP measurement technique, BP rechecks, SPC prescribing, and HTN control? Methods: The study took place in 2025 at a FQHC in Rochester, NY. A quantitative descriptive design was utilized and data analysis included descriptive statistics and Repeat Measures Analysis of Variance (ANOVA) test. Components implemented: a) Patient registry/outreach Inclusion criteria (IC): 1) patients 18-85yo with a known diagnosis of HTN 2) on ≤ 2 antihypertensive medications 3) previous two BP readings ≥ 140/90 4) last visit was <12 months ago and have no visit scheduled in the next 3 months Outcomes measured: HTN Management Visit (HMV) with PharmD b) EHR Alert for repeat BP check IC: all patients seen by providers Outcomes measured: repeat BP obtained when initial BP ≥140/90 c) Education for nurses on BP measurement technique IC: all staff (MA, LPN, RN) who room patients Outcomes measured: Quick Check Assessment tool from AHA performed pre- and post-educational intervention d) Promote use of SPC to treat HTN IC: all primary care providers and PharmDs Outcomes measured: prescriptions for SPC therapy e) PharmD-led HMVs IC: patients from HTN Registry/Referrals who participated in the HMV with PharmD Outcomes measured: SBP measured pre- and post-HMV Results: a) EHR alerts for repeat BP check - Appropriate repeat BP measurement increased from 67% to > 90% (n= 670, 606 repeats performed). b) Education for nurses on BP technique - Baseline Quick Checks (n=55 observations) showed common errors and most domains improved on repeat observation (n = 45). c) Promote use of SPC - SPC prescribing doubled from baseline of 12% to 24% (n = 544 SPC prescribed). d) PharmD-led HMV - Average SBP change from the patients’ first HMV to their second HMV was -17 mm Hg with a strong statistical significance noted (p <.001). In terms of HTN control, 39% (n=10/26) reached BP ≤130/80 and 73% (n=19/26) reached BP ≤140/90. Conclusion: Implementing select components from the HMP Toolkit resulted in improved repeat BP rates, improved BP measurement technique, and increased SPC prescribing rates. Additionally, patients who participated in the PharmD-led HMVs saw an average 17 mm Hg reduction in SBP with 73% of these patients reaching target BP of ≤140/90.